07.05.2014 • Topics

'People, Infrastructure and Processes that Differ Remarkably from Competitors'

Dr. Rolf Kuropka, managing director, Krahn Chemie
Dr. Rolf Kuropka, managing director, Krahn Chemie

What kind of growth do you aspire to in the next few years; in which sectors, markets or regions do you see significant growth opportunities?

Krahn Chemie will consequently follow its growth strategy: regional expansion to countries attractive for distributors and strengthening of the product portfolio of the segments Krahn Chemie is active in, i.e., coatings and construction chemicals, plastics, rubber, technical ceramics, adhesives, and lubricants. We still believe that even in a quite mature market like the EU, a company can gain additional market share by offering people, infrastructure and processes that differ remarkably from competitors.

How do you intend to implement these plans and seize these opportunities?

With the acquisition of the ICH Benelux Group in 2013 and more recently Pietro Carini in Italy, Krahn Chemie took two major steps to expand its market position in Europe and to strengthen its portfolio and competencies. We will continue to follow this path, and we also go on winning attractive distributions rights of the tier 1 suppliers of the world. Our central laboratory in Bottrop as well as local laboratories in the main region will support our technically driven approach. The target is to become the preferred specialty chemical distributor in Europe.

 

Company

Krahn Chemie

Mühlenhagen 35
20539 Hamburg
Germany

Company contact







Virtual Event

High Performance Food Production
Perfection Starts in the Tank

High Performance Food Production

March 24, 2026 | Optimize your food production with smarter mixing—join the Ystral seminar to discover 20 real-world applications that cut processing times, reduce costs, and boost product quality.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read